Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Cited by (1,026)

Items 301–400 of 1,026

1. Relationship between B7-H4, Regulatory T Cells, and Patient Outcome in Human Ovarian Carcinoma
   Ilona Kryczek, Shuang Wei, Gefeng Zhu, Leann Myers, Peter J. Mottram, Pui Joan Cheng, Lieping Chen, George Coukos, Weiping Zou · 2007 · Cancer Research
2. The B7 Family and Cancer Therapy: Costimulation and Coinhibition
   Xingxing Zang, James Patrick Allison · 2007 · Clinical Cancer Research
3. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance
   Verma, Vivek, Shrimali, Rajeev K, Ahmad, Shamim, Dai, Winjie, Wang, Hua, Lu, Sumin, Nandre, Rahul, Gaur, Pankaj, Lopez, Jose, Sade-Feldman, Moshe et al. · 2019 · Nature Immunology
4. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
   Simone E. Muenst, Savas Deniz Soysal, Feng Gao, Ellen Christina Obermann, Daniel Oertli, William E. Gillanders · 2013 · Breast Cancer Research and Treatment
5. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
   Jang‐June Park, Ryusuke Omiya, Yumiko Matsumura, Yukimi Sakoda, Atsuo Kuramasu, Mathew M. Augustine, Sheng Yao, Fumihiko Tsushima, Hidehiko Narazaki, Sudarshan Anand et al. · 2010 · Blood
6. Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells
   Xun Wang, Lingyun Yang, Feng Huang, Qiuyang Zhang, Sen Liu, Lin Ma, Zongbing You · 2017 · Immunology Letters
7. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
   Faje, Alexander · 2016 · Pituitary
8. Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
   Esdy N. Rozali, Stanleyson V. Hato, Bruce W. S. Robinson, Richard Lake, Willem Joost Lesterhuis · 2012 · Clinical and Developmental Immunology
9. Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
   David Jacob Andorsky, Reiko E. Yamada, JONATHAN W. SAID, Geraldine S. Pinkus, David J. Betting, John M. Timmerman · 2011 · Clinical Cancer Research
10. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas
    Joseph Flores‐Toro, Defang Luo, Adithya Gopinath, Matthew R. Sarkisian, James J. Campbell, Israel F. Charo, Rajinder Singh, Thomas J. Schall, Meenal Datta, Rakesh K. Jain et al. · 2019 · Proceedings of the National Academy of Sciences
11. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
    Lijie Zhai, Stefani Spranger, David C. Binder, Galina Gritsina, Kristen L. Lauing, Francis Joseph Giles, Derek Alan Wainwright · 2015 · Clinical Cancer Research
12. PD ‐L1 expression is mainly regulated by interferon gamma associated with JAK ‐ STAT pathway in gastric cancer
    Kousaku Mimura, Jun Liang Teh, Hirokazu Okayama, Kensuke Shiraishi, Ley‐Fang Kua, Vivien Koh, Duane T. Smoot, Hassan Ashktorab, Takahiro Oike, Yoshiyuki Suzuki et al. · 2017 · Cancer Science
13. Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
    Maxine Sun, Shahrokh François Shariat, Christopher Wai-Sam Cheng, Vincenzo Ficarra, Masaru Murai, Stéphane Marie. Oudard, Allan J. Pantuck, Richard E. Zigeuner, Pierre I. Karakiewicz · 2011 · European Urology
14. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
    Clémence Granier, Éléonore De Guillebon, Charlotte Blanc, Helene Roussel, Cécile Badoual, Elia Colin, Antonin Saldmann, Alain Gey, Stéphane Marie. Oudard, Éric Tartour · 2017 · ESMO Open
15. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy
    Liu, Yuting, Zugazagoitia, Jon, Ahmed, Fahad Shabbir, Henick, Brian S., Gettinger, Scott N., Herbst, Roy S., Schalper, Kurt A., Rimm, David L. · 2020 · Clinical Cancer Research
16. Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
    Markus Y. Mapara, Megan Sykes · 2004 · Journal of Clinical Oncology
17. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
    Delphine Rossille A, M Gressier, Diane Damotte, Delphine Maucort‐Boulch, Céline Pangault, G. Sémana, Steven Le Gouill, Corinne Haïoun, Karin Tarte, T Lamy et al. · 2014 · Leukemia
18. Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
    Lawrence H. Fong, Eric Jay Small · 2008 · Journal of Clinical Oncology
19. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
    Daixi Ren, Yuze Hua, Boyao Yu, Xin Ye, Ziheng He, Chunwei Li, Jie Wang, Yongzhen Mo, Xiaoxu Wei, Yunhua Chen et al. · 2020 · Molecular Cancer
20. Emerging Opportunities and Challenges in Cancer Immunotherapy
    Theresa L. Whiteside, Sandra Demaria, Maria Esperanza Rodriguez-Ruiz, Hassane M. Zarour, Ignacio Melero · 2016 · Clinical Cancer Research
21. IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction
    Jabri, Bana, Abadie, Valérie · 2015 · Nature Reviews Immunology
22. PD-1/PD-L1 and immunotherapy for pancreatic cancer
    Mengyu Feng, Guangbing Xiong, Zhe Cao, Gang Yang, Suli Zheng, Xujun Song, Lei You, Lianfang Zheng, Taiping Zhang, Yupei Zhao · 2017 · Cancer Letters
23. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
    Patcharee Ritprajak, Miyuki Azuma · 2014 · Oral Oncology
24. Oncolytic virus immunotherapy: future prospects for oncology
    Junaid Y. Raja, Johannes Maximilian Ludwig, Scott N. Gettinger, Kurt Alex Schalper, Hyun S. Kim · 2018 · Journal for ImmunoTherapy of Cancer
25. B7-H3 and B7-H4 expression in non-small-cell lung cancer
    Yuping Sun, Yunshan Wang, Jianqiang Zhao, Ming Gu, Ricardo Giscombe, Ann Kari Lefvert, Xiongbiao Wang · 2006 · Lung Cancer
26. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia
    Xi Wang, Jinge Li, Ke Dong, Lin Fang, Min Long, Yongri Ouyang, Junxia Wei, Xi Chen, Yuanyuan Weng, Ting He et al. · 2014 · Cellular Signalling
27. PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses against Tumor
    Liangrong Shi, Lujun Chen, Changping Wu, Yibei Zhu, Bin Xu, Xiao Wei Zheng, Mingfen Sun, Wen Wen, Xichao Dai, Min Yang et al. · 2016 · Clinical Cancer Research
28. Combining Epigenetic and Immunotherapy to Combat Cancer
    Katherine Bakshian Chiappinelli, Cynthia A. Zahnow, Nita Ahuja, Stephen B. Baylin · 2016 · Cancer Research
29. PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
    María Gato, Miren Zuazo, Hugo Arasanz, María Ibáñez-Vea, Laura de Lorenzo, G. Fernández-Hinojal, Ruth Vera, Cristian Smerdou, Eva Martišová, Imanol Arozarena et al. · 2017 · Cell Reports
30. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
    Görgün, Güllü, Samur, Mehmet K., Cowens, Kristen B., Paula, Steven, Bianchi, Giada, Anderson, Julie E., White, Randie E., Singh, Ahaana, Ohguchi, Hiroto, Suzuki, Rikio et al. · 2015 · Clinical Cancer Research
31. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
    Li Shi, Shaohua Chen, Lijian Yang, Yangqiu Li · 2013 · Journal of Hematology & Oncology
32. Immunotherapy and tumor microenvironment
    Haidong Tang, Jian Qiao, Yang‐Xin Fu · 2015 · Cancer Letters
33. Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review
    Saleh Daher, Muhammad Massarwa, Ariel A. Benson, Tawfik Khoury · 2017 · Journal of Clinical and Translational Hepatology
34. The immune system and cancer evasion strategies: therapeutic concepts
    Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., Hoeller, S. · 2016 · Journal of Internal Medicine
35. B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival
    Amy Elizabeth Krambeck, Robert Houston Thompson, Haidong Dong, Christine Marie Lohse, Eugene S. Park, Susan M. Kuntz, Bradley C. Leibovich, Michael L. Blute, John C. Cheville, Eugene D. Kwon · 2006 · Proceedings of the National Academy of Sciences
36. FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells
    Meng, Xiangbo, Liu, Xiwei, Guo, Xingdong, Jiang, Shutan, Chen, Tingting, Hu, Zhiqiang, Liu, Haifeng, Bai, Yibing, Xue, Manman, Hu, Ronggui et al. · 2018 · Nature
37. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
    H. Raza Ali, Silvia-Elena Glont, Fiona M. Blows, Elena Provenzano, Sarah‐Jane Dawson, B. Liu, Louise Hiller, Janet Dunn, C. J. Poole, Sarah Jane Bowden et al. · 2015 · Annals of Oncology
38. Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade
    Jeffrey S. Weber · 2010 · Seminars in Oncology
39. Cancer and the Immune System: Basic Concepts and Targets for Intervention
    Drew M. Pardoll · 2015 · Seminars in Oncology
40. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor–Modified T Cells Engineered to Secrete Checkpoint Inhibitors
    Si Li, Natnaree Siriwon, Xiaoyang Zhang, Shuai Yang, Tao Jin, Feng He, Kwang Gi Kim, John Mac, Zhengfei Lu, S P Wang et al. · 2017 · Clinical Cancer Research
41. Inhibition of T–Cell Responses by Hepatic Stellate Cells Via B7–H1-Mediated T–Cell Apoptosis in Mice
    Yu, Ming–Chin, Chen, Cheng–Hsu, Liang, Xiaoyan, Wang, Lianfu, Gandhi, Chandrashekhar R., Fung, John J., Lu, Lina, Qian, Shiguang · 2004 · Hepatology
42. Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer
    M. Ratcliffe, Alan D. Sharpe, Anita Midha, Craig Barker, Marietta Louise Juanita Scott, Paul Scorer, Hytham Al‐Masri, Marlon Cezar Rebelatto, Jill Walker · 2017 · Clinical Cancer Research
43. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
    Takuro Noguchi, Jeffrey P. Ward, Matthew M. Gubin, Cora D. Arthur, Sang Hun Lee, Jasreet Hundal, Mark J. Selby, Robert F. Graziano, Elaine R. Mardis, Alan J. Korman et al. · 2017 · Cancer Immunology Research
44. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
    Xinxin Zhu, Jinghe Lang · 2017 · Oncotarget
45. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
    Sandra P. D’Angelo, Alexander Noor Shoushtari, Narasimhan P. Agaram, Deborah Kuk, Li‐Xuan Qin, Richard D. Carvajal, Mark Andrew Dickson, Mrinal M. Gounder, Mary Louise Keohan, Gary K. Schwartz et al. · 2014 · Human Pathology
46. Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation
    Heng Zhang, Yu Han, Yuanfan Yang, Feng Lin, Kexin Li, Linghao Kong, Hongxiang Liu, Yongjun Dang, Jian Lin, Peng R. Chen · 2021 · Journal of the American Chemical Society
47. The intracellular signalosome of PD-L1 in cancer cells
    David Escors, María Gato, Miren Zuazo, Hugo Arasanz, María Jesús García-Granda, Ruth Vera, Grazyna T. Kochan · 2018 · Signal Transduction and Targeted Therapy
48. A snapshot of the PD-1/PD-L1 pathway
    Chinmoy Ghosh, Gary Luong, Yue Sun · 2021 · Journal of Cancer
49. Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses <i>in vitro</i>
    Blank, Christian, Kuball, Juergen, Voelkl, Simon, Wiendl, Heinz, Becker, Bernd, Walter, Bernhard, Majdic, Otto, Gajewski, Thomas F., Theobald, Mathias, Andreesen, Reinhard et al. · 2006 · International Journal of Cancer
50. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
    Xi-Wen Bi, Hua Wang, Wen-wen Zhang, Jing‐Hua Wang, Wen-jian Liu, Zhong-Jun Xia, Hui-Qiang Huang, Wen‐qi Jiang, Yu Jing Zhang, Liang Wang · 2016 · Journal of Hematology & Oncology
51. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
    Ioannis Zerdes, Alexios Matikas, Jonas C. S. Bergh, George Z. Rassidakis, Theodoros Foukakis · 2018 · Oncogene
52. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
    Erin E. West, Hyun‐Tak Jin, Ata Ur Rasheed, Pablo Penaloza‐MacMaster, Sang‐Jun Ha, Wendy G. Tan, Ben Youngblood, Gordon James Freeman, Kendall A. Smith, Rafi Ahmed · 2013 · Journal of Clinical Investigation
53. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer
    Emma Nolan, Peter Stephen Savas, Antonia N. Policheni, Phillip Kevin Darcy, François Vaillant, Christopher Mintoff, Sathana Dushyanthen, Mariam Mansour, Jia‐Min Pang, Stephen B. Fox et al. · 2017 · Science Translational Medicine
54. An aberrant STAT pathway is central to COVID-19
    T. Matsuyama, Shawn P. Kubli, Steven K. Yoshinaga, Klaus Pfeffer, Tak W. Mak · 2020 · Cell Death and Differentiation
55. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
    Zijun Yidan Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H. Young · 2017 · Frontiers in Immunology
56. Pembrolizumab for the treatment of non-small cell lung cancer
    Sung Hee Lim, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn · 2016 · Expert Opinion on Biological Therapy
57. Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction
    Shengdian Wang, Jürgen Bajorath, Dallas B. Flies, Haidong Dong, Tasuku Honjo, Lieping Chen · 2003 · The Journal of Experimental Medicine
58. TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
    Park, Benjamin V., Freeman, Zachary T., Ghasemzadeh, Ali, Chattergoon, Michael A., Rutebemberwa, Alleluiah, Steigner, Jordana, Winter, Matthew E., Huynh, Thanh V., Sebald, Suzanne M., Lee, Se-Jin et al. · 2016 · Cancer Discovery
59. Emerging phagocytosis checkpoints in cancer immunotherapy
    Yue Liu, Yanjin Wang, Yanrong Yang, Linjun Weng, Qi Wu, Jin Zhang, Pengcheng Zhao, Lan Fang, Yufeng Shi, Ping Wang · 2023 · Signal Transduction and Targeted Therapy
60. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
    James L. Gulley, Arun Rajan, David Robert Spigel, Nicholas O. Iannotti, Jason Claud Chandler, Deborah Jean Lee Wong, Joseph W. Leach, W. Jeff Edenfield, Ding Wang, Hans Juergen Grote et al. · 2017 · The Lancet Oncology
61. Emerging role of natural products in cancer immunotherapy
    Songtao Dong, Xiangnan Guo, Fei Han, Zhonggui He, Yongjun Wang · 2021 · Acta Pharmaceutica Sinica B
62. Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
    Jung Ryul Kim, Young Jae Moon, Keun Sang Kwon, Jun Sang Bae, Sajeev Wagle, Kyoung Min Kim, Ho Sung Park, Ho Lee, Woo Sung Moon, Myoung Ja Chung et al. · 2013 · PLoS ONE
63. Costimulatory and coinhibitory receptors in anti‐tumor immunity
    Grégory Driessens, Justin Paul Kline, Thomas Frank Gajewski · 2009 · Immunological Reviews
64. PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
    Jacalyn M. Rosenblatt, Brett E. Glotzbecker, Heidi Mills, Baldev Vasir, Dimitrios Tzachanis, James D. Levine, Robin Joyce, Kerry Wellenstein, Whitney Keefe, Michael Schickler et al. · 2011 · Journal of Immunotherapy
65. Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses
    Frann Bennett, Deborah P. Luxenberg, Vincent Ling, I‐Ming Wang, Kimberly Marquette, David Lowe, Nighat Khan, Geertruida M. Veldman, Kenneth A. Jacobs, Viia E. Valge-archer et al. · 2003 · The Journal of Immunology
66. Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
    Rajen J. Mody, Arlene H. Naranjo, Collin Van Ryn, Alice Lin-Tsing Yu, Wendy B. London, Barry Lynn Shulkin, Marguerite T. Parisi, Sabah E. Servaes, Mitchell B. Diccianni, Paul M. Sondel et al. · 2017 · The Lancet Oncology
67. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
    Lionel Apétoh, Sylvain Ladoire, George Coukos, François Ghiringhelli · 2015 · Annals of Oncology
68. Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy via Immune Activation and Checkpoint Inhibition
    Yao Li, Ruifang Zhao, Keman Cheng, Kaiyue Zhang, Yazhou Wang, Yinlong Zhang, Yujing Li, Guangna Liu, Junchao Xu, Jiaqi Xu et al. · 2020 · ACS Nano
69. Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression
    Leticia P. Corrales, Daniel Ajona, Stavros Rafail, Juan José Lasarte, José Ignacio Riezu‐Boj, John D. Lambris, Ana Rouzaut, Maria Jose Pajares, Luis M. Montuenga, Rubén Pı́o · 2012 · The Journal of Immunology
70. Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway
    Jun Wei, Jason Barr, Ling-Yuan Kong, Yongtao Wang, Adam Wu, Amit K. Sharma, Joy Gumin, Verlene K. Henry, Howard Colman, Waldemar Priebe et al. · 2010 · Molecular Cancer Therapeutics
71. Immunotherapy in melanoma: Recent advances and future directions
    Cindy Franklin, Elisabeth Livingstone, Alexander Roesch, Bastian Schilling, Dirk Schadendorf · 2016 · European Journal of Surgical Oncology
72. B7-H1 pathway and its role in the evasion of tumor immunity
    Haidong Dong, Lieping Chen · 2003 · Journal of Molecular Medicine
73. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
    Sergio A. Quezada, Karl S. Peggs, Tyler R. Simpson, James Patrick Allison · 2011 · Immunological Reviews
74. Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis
    Bettina Schreiner, Meike Mitsdoerffer, Bernd C. Kieseier, Lieping Chen, Hans-Peter Hartung, Michael Weller, Heinz Wiendl · 2004 · Journal of Neuroimmunology
75. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
    Annie A. Wu, Virginia E. Drake, Huai-Shiuan Huang, ShihChi Chiu, Lei Zheng · 2015 · OncoImmunology
76. Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma
    Paul L. Crispen, Yuri M. Sheinin, Timothy J. Roth, Christine Marie Lohse, Susan M. Kuntz, Xavier Frigola, Robert Houston Thompson, Stephen Anthony Boorjian, Haidong Dong, Bradley C. Leibovich et al. · 2008 · Clinical Cancer Research
77. Combined Magnetic Hyperthermia and Immune Therapy for Primary and Metastatic Tumor Treatments
    Jiong Pan, Ping Hu, Yuedong Guo, Junnian Hao, Dalong Ni, Yingying Xu, Qunqun Bao, Heliang Yao, Chenyang Wei, Qingsheng Wu et al. · 2020 · ACS Nano
78. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis.
    Sabine Wintterle, Bettina Schreiner, Meike Mitsdoerffer, Dagmar Schneider, Lieping Chen, Richard Meyermann, Michael Weller, Heinz Wiendl · 2003 · PubMed
79. T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival
    Stephen Anthony Boorjian, Yuri M. Sheinin, Paul L. Crispen, Sara A. Farmer, Christine Marie Lohse, Susan M. Kuntz, Bradley C. Leibovich, Eugene D. Kwon, Igor Frank · 2008 · Clinical Cancer Research
80. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma
    Gaixia He, Henghui Zhang, Jinxue Zhou, Beibei Wang, Yanhui Chen, Yaxian Kong, Xingwang Xie, Xueyan Wang, Ran Fei, Lai Wei et al. · 2015 · Journal of Experimental & Clinical Cancer Research
81. LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
    Yayi He, Hui Yu, Leslie M. Rozeboom, Christopher J. Rivard, Kim E. Ellison, Rafał Dziadziuszko, Kenichi Suda, Shengxiang Ren, Chunyan Wu, Likun Hou et al. · 2017 · Journal of Thoracic Oncology
82. B7-H3 Ligand Expression by Prostate Cancer: A Novel Marker of Prognosis and Potential Target for Therapy
    Roth, Timothy J., Sheinin, Yuri, Lohse, Christine M., Kuntz, Susan M., Frigola, Xavier, Inman, Brant A., Krambeck, Amy E., Mckenney, Maureen E., Karnes, R. Jeffrey, Blute, Michael L. et al. · 2007 · Cancer Research
83. Advances in targeting cell surface signalling molecules for immune modulation
    Sheng Yao, Yuwen Zhu, Lieping Chen · 2013 · Nature Reviews Drug Discovery
84. Functions of Immune Checkpoint Molecules Beyond Immune Evasion
    Yaping Zhang, Junke Zheng · 2020 · Advances in experimental medicine and biology
85. PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
    Song, Minmin, Chen, Defeng, Lu, Biyan, Wang, Chenliang, Zhang, Junxiao, Huang, Lanlan, Wang, Xiaoyan, Timmons, Christine L., Hu, Jun, Liu, Bindong et al. · 2013 · PLoS ONE
86. The promise of cancer vaccines
    Eli Gilboa · 2004 · Nature reviews. Cancer
87. Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues
    Edwin Roger Parra, Naohiro Uraoka, Mei Jiang, Pamela Cook, Don Lynn Gibbons, Marie‐Andrée Forget, Chantale Bernatchez, Cara Haymaker, Ignacio Ivan Wistuba, Jaime Rodriguez‐Canales · 2017 · Scientific Reports
88. Challenges in developing personalized neoantigen cancer vaccines
    Peter D. Katsikis, Ken J. Ishii, Christopher Schliehe · 2023 · Nature reviews. Immunology
89. Immune Evasion Strategies of Glioblastoma
    Seyed‐Mostafa Razavi, Karen E. Lee, Benjamin E. Jin, Parvir S. Aujla, Sharareh Gholamin, Gordon Li · 2016 · Frontiers in Surgery
90. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
    Chunwan Lu, Amy V. Paschall, Huidong Shi, Natasha M. Savage, Jennifer L. Waller, Maria Eugenia Sabbatini, Nicholas H. Oberlies, Cedric J. Pearce, Kebin Liu · 2016 · JNCI Journal of the National Cancer Institute
91. IFN-γ: A cytokine at the right time, is in the right place
    J. D. Burke, Howard A. Young · 2019 · Seminars in Immunology
92. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
    Ping Zhang, Dongming Su, Mei Liang, Jian Fu · 2007 · Molecular Immunology
93. Identification of CD8 + CD25 + Foxp3 + suppressive T cells in colorectal cancer tissue
    Nathalie Chaput, Samy Louafi, Armelle Bardier–Dupas, Frédéric Charlotte, J.C. Vaillant, F. Ménégaux, Michèlle Rosenzwajg, Francois Michel Lemoine, David Klatzmann, Julien Taı̈eb · 2008 · Gut
94. Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications
    Md Nurul Huda, Md Nafiujjaman, Isaac G. Deaguero, Jude Okonkwo, Meghan L. Hill, Tae Ho Kim, Md Nurunnabi · 2021 · ACS Biomaterials Science & Engineering
95. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
    Shengjie Tang, Chao Qin, Haiyang Hu, Tao Liu, Yiwei He, Haiyang Guo, Hang Yan, Jun Zhang, Shoujun Tang, Haining Zhou · 2022 · Cells
96. Immune Suppression in the Tumor Microenvironment
    Thomas Frank Gajewski, Yuru Meng, Helena Harlin · 2006 · Journal of Immunotherapy
97. B7-H1 (Programmed Death-1 Ligand) on Dendritic Cells Is Involved in the Induction and Maintenance of T Cell Anergy
    Nicole Selenko-Gebauer, Otto Majdic, Andreas Szekeres, Gerald Höfler, Elisabeth Guthann, Ulf Korthäuer, Gerhard J. Zlabinger, Peter Steinberger, Winfried Franz Pickl, Hannes S. J. Stockinger et al. · 2003 · The Journal of Immunology
98. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
    Xin Jin, Donglin Ding, Yuqian Yan, Hui Li, Bo Wang, Linlin Ma, Zhenqing Ye, Tao Ma, Qiang Wu, Daniel Nava Rodrigues et al. · 2018 · Molecular Cell
99. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): An open-label, dose-finding and dose-expansion, phase 1b trial
    Choueiri, Toni K, Larkin, James, Oya, Mototsugu, Thistlethwaite, Fiona, Martignoni, Marcella, Nathan, Paul, Powles, Thomas, McDermott, David, Robbins, Paul B, Chism, David D et al. · 2018 · The Lancet Oncology
100. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells
     Nazareth, Michael R, Broderick, Lori, Simpson-Abelson, Michelle R, Kelleher, Raymond J, Yokota, Sandra J, Bankert, Richard B · 2007 · The Journal of Immunology